Musculoskeletal PainPhase 1NCT06395155
A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers
A Phase 1 study testing DHP2306R1 and DHP2306R2 in people with Musculoskeletal Pain, run by Daehwa Pharmaceutical Co., Ltd. at 1 site in South Korea.
Trial summary
This phase 1 study is to evaluate the safety and pharmacokinetic drug interactions of DHP2306R1 and DHP2306R2 when administered alone and in combination in healthy conditions. Participants will be taken DHP2306R1 and DHP2306R2 alone or combination for 3 period, randomized in six-sequence. Read more about this study
- Who is it for?
- Ages 19 years and olderHealthy volunteers can take part
- Conditions the study is for
- Musculoskeletal Pain
- What is being tested?
- DHP2306R1 and DHP2306R2
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteSouth Korea
- Study dates
- 26 Oct 2023to 7 Dec 2023
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 1) Healthy adult volunteers aged 19 years or older at the time of screening
- 2) At the time of screening, those who weigh more than 50.0 kg and have a body mass index (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less.
- 3) Those who do not have congenital or chronic diseases requiring treatment and no pathological symptoms or findings as a result of internal medical examination
- 4) At the time of screening, those who were determined to be suitable subjects for clinical trials as a result of tests such as clinical laboratory tests, vital signs, physical examination (physical examination), and 12-lead electrocardiogram conducted according to the characteristics of the clinical trial drug.
- 5) A person who, after receiving a detailed explanation of this clinical trial and fully understanding it, voluntarily decides to participate and agrees in writing to comply with the subject compliance requirements during the clinical trial period
Who cannot join
- 1) Current or past medical history of clinically significant liver, kidney, nervous system, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, and musculoskeletal systems, as well as the following symptoms or history. Those who have
- ① Renal impairment
- ② Liver disorder
- 2) For women, pregnant women (Urine-HCG positive) or lactating women
- 3) Persons with a history of hypersensitivity or clinically significant hypersensitivity to DHP2306R1, DHP2306R2, or components of clinical investigational drugs, aspirin, non-steroidal anti-inflammatory drugs (including COX-2 inhibitors), or sulfonamide drugs.
- 4) People with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Show all 29Show fewer
- 5) Those with a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of clinical trial drugs
- 6) At the time of screening, those with clinically significant findings including the following findings on 12-lead electrocardiography
- QTc > 450 ms for men, QTc > 470 ms for women
- PR interval > 200 ms
- QRS duration > 120 ms
- 7) At the time of screening, a person who shows the following results in clinical laboratory tests
- Those whose AST, ALT, ALP, γ-GT and Bilirubin total exceed twice the upper limit of the normal range in clinical laboratory tests to evaluate liver function
- If the blood creatinine level exceeds the reference range or the eGFR calculated by CKD-EPI is less than 60 mL/min/1.73m2
- Those whose CPK exceeds 2.5 times the upper limit of the normal range in clinical laboratory tests
- 8) If you have a history of drug abuse or test positive for drugs of abuse in a urine drug test
- 9) At the time of screening, those who showed vital signs measured in a sitting position after resting for more than 3 minutes include systolic blood pressure ≥ 150 mmHg or ≤ 90 mmHg, diastolic blood pressure ≥ 100 mmHg or ≤ 60 mmHg, and pulse ≤ 40 bpm or ≥ 100 bpm.
- 10) Persons who administered drugs that induce or inhibit drug metabolizing enzymes such as barbiturates within 1 month before the first administration date
- 11) People who eat abnormal diets that may affect the absorption, distribution, metabolism, and excretion of investigational drugs or who consume foods that may affect drug metabolism
- 12) Any prescription drugs or herbal preparations that may affect the characteristics of investigational drugs, including cyclosporine, were administered within 2 weeks before the first administration date, or any over-the-counter drugs (OTC drugs) or vitamin preparations were administered within 10 days. (However, if the drug does not affect the pharmacokinetic properties of the clinical trial drug, the applicant may participate in the clinical trial at the discretion of the investigator.)
- 13) Those who participated in and received treatment in another clinical trial within 6 months prior to the date of first administration (however, the end standard for participation in other clinical trials is based on the date of last administration, and the next day is calculated as 1 day)
- 14) Those who have donated whole blood within 2 months before the first administration date or component blood donation within 1 month, received a blood transfusion within 1 month, or cannot refrain from donating blood from the time of written consent to the time of PSV
- 15) Those who have continuously drank alcohol (exceeding 21 units/week, 1 unit=10 g=12.5 mL of pure alcohol) within 6 months before the first administration date or who are unable to abstain from drinking from the time of written consent to the time of PSV
- 16) Smokers who smoked more than 10 cigarettes on average per day within 3 months before the first administration date and those who were unable to quit smoking from 24 hours before the first administration to the time of the last blood collection in each period
- 17) Those who consumed food containing grapefruit (grapefruit) from 48 hours before the first administration until the time of PSV or who cannot refrain from consuming it
- 18) Those who consumed or were unable to refrain from consuming caffeine-containing foods (coffee, green tea, black tea, carbonated drinks, coffee milk, tonic drinks, etc.) during the period from 24 hours before the first administration in each period until the last blood collection.
- 19) Those who engaged in vigorous exercise exceeding the level of daily life during the period from 48 hours before the first administration to the time of PSV, or who cannot refrain from vigorous exercise
- 20) From the time of written consent until 2 weeks after the last date of administration of the investigational drug, even if you, your spouse, or partner are planning to become pregnant or are not planning to become pregnant, you must use reliable contraceptive methods (e.g., administration of contraceptives and implantation or intrauterine device, sterilization procedure ( Those who are not using vasectomy, tubal ligation, etc.) or barrier methods (combined use of spermicides, condoms, contraceptive diaphragms, vaginal sponges, or cervical caps))
- 21) Persons judged by the investigator to be unsuitable for participation in clinical trials due to reasons other than the above selection/exclusion criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Drug-drug Interactions Between DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers
This phase 1 study is to evaluate the safety and pharmacokinetic drug interactions of DHP2306R1 and DHP2306R2 when administered alone and in combination in healthy conditions.
Participants will be taken DHP2306R1 and DHP2306R2 alone or combination for 3 period, randomized in six-sequence.
- Conditions
- Musculoskeletal Pain
- Being tested
- DHP2306R1, DHP2306R2
- Keywords
- Phase 1, DDI, rheumatoid arthritis, degenerative arthritis, acute pain
- Medical subject headings
- Musculoskeletal Pain, Arthritis, Rheumatoid, Osteoarthritis, Acute Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DHP2306R1Drug
100mg per capsule, BID
DHP2306R2Drug
75mg per Tab, BID
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Experimental | DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day Receives: Drug: DHP2306R1; Drug: DHP2306R2 |
| Sequence B | Experimental | DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day Receives: Drug: DHP2306R1; Drug: DHP2306R2 |
| Sequence C | Experimental | DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day Receives: Drug: DHP2306R1; Drug: DHP2306R2 |
| Sequence D | Experimental | DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period Receives: Drug: DHP2306R1; Drug: DHP2306R2 |
| Sequence E | Experimental | DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period Receives: Drug: DHP2306R1; Drug: DHP2306R2 |
| Sequence F | Experimental | DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period ; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period Receives: Drug: DHP2306R1; Drug: DHP2306R2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUCτ,ss of DHP2306R1 and DHP2306R2
Systemic exposure of DHP2302R1 and DHP2302R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Cmax of DHP2306R1 and DHP2306R2
Plasma concentrations of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Secondary outcomes (6)
AUC0-48 of DHP2306R1 and DHP2306R2
Secondary pharmacokinetic parameters of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
AUCinf of DHP2306R1 and DHP2306R2
Secondary pharmacokinetic parameters of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Tmax of DHP2306R1 and DHP2306R2
Secondary pharmacokinetic parameters of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
t1/2 of DHP2306R1 and DHP2306R2
Secondary pharmacokinetic parameters of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
CL/F of DHP2306R1 and DHP2306R2
Secondary pharmacokinetic parameters of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Vz/F of DHP2306R1 and DHP2306R2
Secondary pharmacokinetic parameters of DHP2306R1 and DHP2306R2
Measured: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2024
- Study start26 Oct 2023
- Primary completion7 Dec 2023
- Study completion7 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Musculoskeletal PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, Open-label, Multiple-dose, Six-sequence, Three-period, Three-treatment, Crossover
- Masking
- None (open label)
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Min Kyu Park, Principal investigator, Chungbuk National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06395155
- Sponsor's protocol ID
- 2306CS-1
- Status last verified
- Oct 2023
- First submitted
- 7 Nov 2023
- Last updated
- 25 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Drug-drug Interactions Between DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers
- ClinicalTrials.gov ID
- NCT06395155
- Acronym / sponsor ID
- 2306CS-1
- Conditions
- Musculoskeletal Pain
- Keywords
- Phase 1, DDI, rheumatoid arthritis, degenerative arthritis, acute pain
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Daehwa Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 26 Oct 2023 (actual)
- Primary completion
- 7 Dec 2023 (actual)
- Study completion
- 7 Dec 2023 (actual)
- First posted
- 2 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase 1 study is to evaluate the safety and pharmacokinetic drug interactions of DHP2306R1 and DHP2306R2 when administered alone and in combination in healthy conditions.
Participants will be taken DHP2306R1 and DHP2306R2 alone or combination for 3 period, randomized in six-sequence.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- Randomized, Open-label, Multiple-dose, Six-sequence, Three-period, Three-treatment, Crossover
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Experimental | Drug: DHP2306R1, Drug: DHP2306R2DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day |
| Sequence B | Experimental | Drug: DHP2306R1, Drug: DHP2306R2DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day |
| Sequence C | Experimental | Drug: DHP2306R1, Drug: DHP2306R2DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day |
| Sequence D | Experimental | Drug: DHP2306R1, Drug: DHP2306R2DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period |
| Sequence E | Experimental | Drug: DHP2306R1, Drug: DHP2306R2DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period |
| Sequence F | Experimental | Drug: DHP2306R1, Drug: DHP2306R2DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period ; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 1) Healthy adult volunteers aged 19 years or older at the time of screening
- 2) At the time of screening, those who weigh more than 50.0 kg and have a body mass index (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less.
- 3) Those who do not have congenital or chronic diseases requiring treatment and no pathological symptoms or findings as a result of internal medical examination
- 4) At the time of screening, those who were determined to be suitable subjects for clinical trials as a result of tests such as clinical laboratory tests, vital signs, physical examination (physical examination), and 12-lead electrocardiogram conducted according to the characteristics of the clinical trial drug.
- 5) A person who, after receiving a detailed explanation of this clinical trial and fully understanding it, voluntarily decides to participate and agrees in writing to comply with the subject compliance requirements during the clinical trial period
Key exclusion criteria (29 listed)
- 1) Current or past medical history of clinically significant liver, kidney, nervous system, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, and musculoskeletal systems, as well as the following symptoms or history. Those who have
- ① Renal impairment
- ② Liver disorder
- 2) For women, pregnant women (Urine-HCG positive) or lactating women
- 3) Persons with a history of hypersensitivity or clinically significant hypersensitivity to DHP2306R1, DHP2306R2, or components of clinical investigational drugs, aspirin, non-steroidal anti-inflammatory drugs (including COX-2 inhibitors), or sulfonamide drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DHP2306R1100mg per capsule, BID | Drug | Sequence A, Sequence B, Sequence C, Sequence D, Sequence E, Sequence F |
| DHP2306R275mg per Tab, BID | Drug | Sequence A, Sequence B, Sequence C, Sequence D, Sequence E, Sequence F |
Primary outcome
AUCτ,ss of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Systemic exposure of DHP2302R1 and DHP2302R2
Cmax of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Plasma concentrations of DHP2306R1 and DHP2306R2
6 secondary outcomes
AUC0-48 of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
AUCinf of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Tmax of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
t1/2 of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
CL/F of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Vz/F of DHP2306R1 and DHP2306R2
Time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jul 2024.
Related trials for Musculoskeletal Pain
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Recruiting
Effects of Telerehabilitation Versus Supervised Rehabilitation Protocol on Pain, Range of Motion and Functional Recovery in Patients With Patellofemoral Pain Syndrome.
Patello Femoral Pain Syndrome
Recruiting
Hybrid mHealth and Telerehabilitation vs Conventional Physiotherapy for Subacromial Pain Syndrome
Subacromial Pain Syndrome
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
RecruitingPhase 4
Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy
Femoracetabular Impingement, Hip Arthroscopy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Min Kyu Park principal investigator
Chungbuk National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DHP2306R1 and DHP2306R2 in people with Musculoskeletal Pain, run by Daehwa Pharmaceutical Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUCτ,ss of DHP2306R1 and DHP2306R2 (time frame: At baseline(Day 1 0 hours), Administration day (Day 4 to Day 5) in each period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jul 2024.